Search This Blog

Sunday, October 25, 2026

Summit Phase III ivonescimab plus chemo improves survival vs durvalumab in advanced biliary tract cancer

 

Summit Therapeutics' Phase III HARMONi-GI1 shows ivonescimab plus chemotherapy significantly improves survival vs durvalumab in advanced biliary tract cancer

  • Ivonescimab plus chemotherapy achieved statistically significant overall survival and progression-free survival superiority versus durvalumab plus chemotherapy.
  • Safety profile for ivonescimab plus chemotherapy described as manageable in advanced biliary tract cancer patients in HARMONi-GI1.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)